1
|
Filgueira CS, Igo SR, Wang DK, Hirsch M, Schulz DG, Bruckner BA, Grattoni A. Technologies for intrapericardial delivery of therapeutics and cells. Adv Drug Deliv Rev 2019; 151-152:222-232. [PMID: 30797957 DOI: 10.1016/j.addr.2019.02.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 02/13/2019] [Accepted: 02/15/2019] [Indexed: 12/12/2022]
Abstract
The pericardium, which surrounds the heart, provides a unique enclosed volume and a site for the delivery of agents to the heart and coronary arteries. While strategies for targeting the delivery of therapeutics to the heart are lacking, various technologies and nanodelivery approaches are emerging as promising methods for site specific delivery to increase therapeutic myocardial retention, efficacy, and bioactivity, while decreasing undesired systemic effects. Here, we provide a literature review of various approaches for intrapericardial delivery of agents. Emphasis is given to sustained delivery approaches (pumps and catheters) and localized release (patches, drug eluting stents, and support devices and meshes). Further, minimally invasive access techniques, pericardial access devices, pericardial washout and fluid analysis, as well as therapeutic and cell delivery vehicles are presented. Finally, several promising new therapeutic targets to treat heart diseases are highlighted.
Collapse
|
2
|
Maslov M, Foianini S, Lovich M. Delivery of drugs, growth factors, genes and stem cells via intrapericardial, epicardial and intramyocardial routes for sustained local targeted therapy of myocardial disease. Expert Opin Drug Deliv 2017; 14:1227-1239. [PMID: 28276968 DOI: 10.1080/17425247.2017.1292249] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Local myocardial delivery (LMD) of therapeutic agents is a promising strategy that aims to treat various myocardial pathologies. It is designed to deliver agents directly to the myocardium and minimize their extracardiac concentrations and side effects. LMD aims to enhance outcomes of existing therapies by broadening their therapeutic window and to utilize new agents that could not be otherwise be implemented systemically. Areas covered: This article provides a historical overview of six decades LMD evolution in terms of the approaches, including intrapericardial, epicardial, and intramyocardial delivery, and the wide array of classes of agents used to treat myocardial pathologies. We examines delivery of pharmaceutical compounds, targeted gene transfection and cell implantation techniques to produce therapeutic effects locally. We outline therapeutic indications, successes and failures as well as technical approaches for LMD. Expert opinion: While LMD is more complicated than conventional oral or intravenous administration, given recent advances in interventional cardiology, it is safe and may provide better therapeutic outcomes. LMD is complex as many factors impact pharmacokinetics and biologic result. The choice between routes of LMD is largely driven not only by the myocardial pathology but also by the nature and physicochemical properties of the therapeutic agents.
Collapse
Affiliation(s)
- Mikhail Maslov
- a Department of Anesthesiology, Pain Medicine and Critical Care , Steward St. Elizabeth's Medical Center/Tufts University School of Medicine , Boston , MA , USA
| | - Stephan Foianini
- a Department of Anesthesiology, Pain Medicine and Critical Care , Steward St. Elizabeth's Medical Center/Tufts University School of Medicine , Boston , MA , USA
| | - Mark Lovich
- a Department of Anesthesiology, Pain Medicine and Critical Care , Steward St. Elizabeth's Medical Center/Tufts University School of Medicine , Boston , MA , USA
| |
Collapse
|
3
|
Macocinschi D, Filip D, Vlad S, Cernatescu C, Tuchilus CG, Gafitanu CA, Dumitriu RP. Electrospun/electrosprayed polyurethane biomembranes with ciprofloxacin and clove oil extract for urinary devices. J BIOACT COMPAT POL 2015. [DOI: 10.1177/0883911515581508] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Polyurethane–eugenol solutions in N,N-dimethyl formamide were electrospun/electrosprayed onto polyurethane–ciprofloxacin biomembranes to obtain drug delivery systems for urinary devices. Following electrospinning/electrospraying, particle-fiber morphology was evidenced by scanning electronic microscope analysis. Contact angle determinations along with surface free energy calculations, moisture diffusion test, and diffusion coefficient determinations were done for polyurethane–ciprofloxacin biomembranes. Determination of bioactive ciprofloxacin release kinetics evidences non-Fickian/anomalous/diffusion mechanism, coupling Fickian diffusion with the relaxation of the polymeric chains within the matrix network. A slight increase in n values for electrospun/electrosprayed coated samples evidenced a behavior closer to a case II transport mechanism with zero-order kinetics. The biological activity of the electrospun/electrosprayed polyurethane membrane samples tested against Staphylococcus aureus, Sarcina lutea, Bacillus cereus, Bacillus subtilis, Escherichia coli, and Pseudomonas aeruginosa showed comparable antibacterial activity with standard ciprofloxacin.
Collapse
Affiliation(s)
- Doina Macocinschi
- Department of Physical Chemistry of Polymers, “Petru Poni” Institute of Macromolecular Chemistry, Iasi, Romania
| | - Daniela Filip
- Department of Physical Chemistry of Polymers, “Petru Poni” Institute of Macromolecular Chemistry, Iasi, Romania
| | - Stelian Vlad
- Department of Physical Chemistry of Polymers, “Petru Poni” Institute of Macromolecular Chemistry, Iasi, Romania
| | - Corina Cernatescu
- Department of Organic, Biochemical and Food Engineering, Faculty of Chemical Engineering and Environmental Protection, “Gheorghe Asachi” Technical University of Iasi, Romania
| | - Cristina Gabriela Tuchilus
- Microbiology Department, Faculty of Medicine, “Gr. T. Popa” University of Medicine and Pharmacy, Iasi, Romania
| | - Carmen Anatolia Gafitanu
- Department of Pharmaceutical Technology, Faculty of Pharmacy, “Gr. T. Popa” University of Medicine and Pharmacy, Iasi, Romania
| | - Raluca Petronela Dumitriu
- Department of Physical Chemistry of Polymers, “Petru Poni” Institute of Macromolecular Chemistry, Iasi, Romania
- University Politehnica of Bucharest, Bucharest, Romania
| |
Collapse
|
4
|
Myocardial drug distribution generated from local epicardial application: potential impact of cardiac capillary perfusion in a swine model using epinephrine. J Control Release 2014; 194:257-65. [PMID: 25234821 DOI: 10.1016/j.jconrel.2014.09.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 08/25/2014] [Accepted: 09/06/2014] [Indexed: 01/27/2023]
Abstract
Prior studies in small mammals have shown that local epicardial application of inotropic compounds drives myocardial contractility without systemic side effects. Myocardial capillary blood flow, however, may be more significant in larger species than in small animals. We hypothesized that bulk perfusion in capillary beds of the large mammalian heart not only enhances drug distribution after local release, but also clears more drug from the tissue target than in small animals. Epicardial (EC) drug releasing systems were used to apply epinephrine to the anterior surface of the left heart of swine in either point-sourced or distributed configurations. Following local application or intravenous (IV) infusion at the same dose rates, hemodynamic responses, epinephrine levels in the coronary sinus and systemic circulation, and drug deposition across the ventricular wall, around the circumference and down the axis, were measured. EC delivery via point-source release generated transmural epinephrine gradients directly beneath the site of application extending into the middle third of the myocardial thickness. Gradients in drug deposition were also observed down the length of the heart and around the circumference toward the lateral wall, but not the interventricular septum. These gradients extended further than might be predicted from simple diffusion. The circumferential distribution following local epinephrine delivery from a distributed source to the entire anterior wall drove drug toward the inferior wall, further than with point-source release, but again, not to the septum. This augmented drug distribution away from the release source, down the axis of the left ventricle, and selectively toward the left heart follows the direction of capillary perfusion away from the anterior descending and circumflex arteries, suggesting a role for the coronary circulation in determining local drug deposition and clearance. The dominant role of the coronary vasculature is further suggested by the elevated drug levels in the coronary sinus effluent. Indeed, plasma levels, hemodynamic responses, and myocardial deposition remote from the point of release were similar following local EC or IV delivery. Therefore, the coronary vasculature shapes the pharmacokinetics of local myocardial delivery of small catecholamine drugs in large animal models. Optimal design of epicardial drug delivery systems must consider the underlying bulk capillary perfusion currents within the tissue to deliver drug to tissue targets and may favor therapeutic molecules with better potential retention in myocardial tissue.
Collapse
|
5
|
Maslov MY, Edelman ER, Wei AE, Pezone MJ, Lovich MA. High concentrations of drug in target tissues following local controlled release are utilized for both drug distribution and biologic effect: an example with epicardial inotropic drug delivery. J Control Release 2013; 171:201-7. [PMID: 23872515 DOI: 10.1016/j.jconrel.2013.06.038] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2013] [Revised: 06/28/2013] [Accepted: 06/29/2013] [Indexed: 12/16/2022]
Abstract
Local drug delivery preferentially loads target tissues with a concentration gradient from the surface or point of release that tapers down to more distant sites. Drug that diffuses down this gradient must be in unbound form, but such drug can only elicit a biologic effect through receptor interactions. Drug excess loads tissues, increasing gradients and driving penetration, but with limited added biological response. We examined the hypothesis that local application reduces dramatically systemic circulating drug levels but leads to significantly higher tissue drug concentration than might be needed with systemic infusion in a rat model of local epicardial inotropic therapy. Epinephrine was infused systemically or released locally to the anterior wall of the heart using a novel polymeric platform that provides steady, sustained release over a range of precise doses. Epinephrine tissue concentration, upregulation of cAMP, and global left ventricular response were measured at equivalent doses and at doses equally effective in raising indices of contractility. The contractile stimulation by epinephrine was linked to drug tissue levels and commensurate cAMP upregulation for IV systemic infusion, but not with local epicardial delivery. Though cAMP was a powerful predictor of contractility with local application, tissue epinephrine levels were high and variable--only a small fraction of the deposited epinephrine was utilized in second messenger signaling and biologic effect. The remainder of deposited drug was likely used in diffusive transport and distribution. Systemic side effects were far more profound with IV infusion which, though it increased contractility, also induced tachycardia and loss of systemic vascular resistance, which were not seen with local application. Local epicardial inotropic delivery illustrates then a paradigm of how target tissues differentially handle and utilize drug compared to systemic infusion.
Collapse
Affiliation(s)
- Mikhail Y Maslov
- Tufts University School of Medicine, Department of Anesthesiology and Pain Medicine, Steward St. Elizabeth's Medical Center, Boston, MA 02135, USA.
| | | | | | | | | |
Collapse
|
6
|
Bolderman RW, Hermans JR, Rademakers LM, de Jong MM, Bruin P, Dias AA, van der Veen FH, Maessen JG. Epicardial application of an amiodarone-releasing hydrogel to suppress atrial tachyarrhythmias. Int J Cardiol 2011; 149:341-6. [DOI: 10.1016/j.ijcard.2010.02.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2009] [Revised: 12/18/2009] [Accepted: 02/06/2010] [Indexed: 01/09/2023]
|
7
|
Bolderman RW, Bruin P, Hermans JJR, Boerakker MJ, Dias AA, van der Veen FH, Maessen JG. Atrium-targeted drug delivery through an amiodarone-eluting bilayered patch. J Thorac Cardiovasc Surg 2010; 140:904-10. [PMID: 20363485 DOI: 10.1016/j.jtcvs.2010.01.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2009] [Revised: 12/18/2009] [Accepted: 01/10/2010] [Indexed: 10/19/2022]
Abstract
OBJECTIVE Clinical studies have demonstrated the efficacy of oral and intravenous amiodarone therapy to prevent postoperative atrial fibrillation. However, because of significant extracardiac side effects, only high-risk patients are eligible for prophylactic amiodarone therapy. This study addressed the hypothesis that atrium-specific drug delivery through an amiodarone-eluting epicardial patch reduces vulnerability to atrial tachyarrhythmias, whereas ventricular and plasma drug concentrations are minimized. METHODS Right atrial epicardiums of goats were fitted with electrodes and a bilayered patch (poly[ethylene glycol]-based matrix and poly[lactide-co-caprolactone] backing layer) loaded with amiodarone (10 mg per patch, n = 10) or without drug (n = 6). Electrophysiologic parameters (atrial effective refractory period, conduction time, and rapid atrial response to burst pacing) and amiodarone levels in plasma and tissue were measured during 1 month's follow-up. RESULTS Epicardial application of amiodarone-eluting patches produced persistently higher drug concentrations in the right atrium than in the left atrium, ventricles, and extracardiac tissues by 2 to 4 orders of magnitude. Atrial effective refractory period and conduction time increased, whereas rapid atrial response inducibility decreased significantly (P < .05) during the 1-month follow-up compared with that seen in animals treated with drug-free patches. Amiodarone concentrations in plasma remained undetectably low (<10 ng/mL). CONCLUSIONS Atrium-specific drug delivery through an amiodarone-eluting patch produces therapeutic atrial drug concentrations, whereas ventricular and systemic drug levels are minimized. This study demonstrates that sustained targeted drug delivery to a specific heart chamber is feasible and might reduce the risk for ventricular and extracardiac adverse effects. Epicardial application of amiodarone-eluting patches is a promising strategy to prevent postoperative atrial fibrillation.
Collapse
Affiliation(s)
- Robert W Bolderman
- Department of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
8
|
Intrapericardial Delivery of Amiodarone and Sotalol: Atrial Transmural Drug Distribution and Electrophysiological Effects. J Cardiovasc Pharmacol 2009; 54:355-63. [DOI: 10.1097/fjc.0b013e3181bad042] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Levy RJ, Labhasetwar V, Strickberger SA, Underwood T, Davis J. Controlled release implant dosage forms for cardiac arrhythmias: Review and perspectives. Drug Deliv 2008; 3:137-42. [DOI: 10.3109/10717549609029442] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
|
11
|
Al Malyan M, Becchi C, Nikkola L, Viitanen P, Boncinelli S, Chiellini F, Ashammakhi N. Polymer-based biodegradable drug delivery systems in pain management. J Craniofac Surg 2006; 17:302-13. [PMID: 16633180 DOI: 10.1097/00001665-200603000-00018] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Pain is an unpleasant sensory experience commonly produced by damage to bodily tissues and it is one of the most significant public health problems, because 21.5% of the world population is estimated to suffer from pain. It results in a total loss of more than 165 billion US dollars each year in the United States alone. Pain reflects a mixture of various pathophysiologic, psychologic, and genetic contributions. When undertreated, pain usually results in serious immune and metabolic upset. Therefore, it requires wide understanding and intensive effort for a better management. Currently, pain control is limited by the modest efficiency of the used drugs, the serious side effects of these drugs, and the inefficacy of conventional drug administration. By the introduction of the technology of biodegradable controlled-release devices into clinical practice, pain control not only benefits from these novel methods for a better delivery of various drugs, but the side effects of the drugs are reduced because use of the devices improves patient compliance. Biodegradable controlled-release devices are polymer-based devices that are designed to deliver drugs locally in a predesigned manner. Recently, there was a high interest in developing these devices for the delivery of different drugs used for pain control. This paper first highlights the dimensions and basics of the problem of pain. Then, it presents an overview of the biodegradable polymers that are used in drug delivery systems and summarizes the studies carried out on these systems in the field of pain management. We refer to our experience in developing a device for multimodal drug delivery, including the use of nanotechnology. Future perspectives are also presented.
Collapse
Affiliation(s)
- Mohamed Al Malyan
- Department of Medical and Surgical Critical Care, Section of Anaesthesia and Intensive Care, Florence University, Florence, Italy
| | | | | | | | | | | | | |
Collapse
|
12
|
van Brakel TJ, Hermans JJR, Janssen BJ, van Essen H, Botterhuis N, Smits JFM, Maessen JG. Intrapericardial Delivery Enhances Cardiac Effects of Sotalol and Atenolol. J Cardiovasc Pharmacol 2004; 44:50-6. [PMID: 15175557 DOI: 10.1097/00005344-200407000-00007] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Targeting drugs to the heart by intrapericardial (i.p.c.) delivery may be a promising strategy to obtain higher drug efficiencies with lesser side effects. We examined whether i.p.c. delivery of sotalol and atenolol in rats offers advantages over intravenous (i.v.) application. Following sustained IPC infusion of sotalol or atenolol, pericardial fluid levels exceeded plasma levels 97 and 134 times respectively (P < 0.01) resulting in 3.8 and 4.7 times higher overall left ventricular tissue drug levels (P < 0.05). In a second experiment, the effects of the i.p.c. or i.v. beta-blocker infusions on nitroprusside-induced tachycardia were studied in conscious rats. For both drugs, i.p.c. infusion of 0.03 mg/kg.h produced similar antitachycardiac effects as the 1 mg/kg.h i.v. dose. In a third set of studies, dP/dt max challenged by dobutamine infusion was assessed to study ventricular contractile function after i.v. and i.p.c. sotalol in anesthetized rats. i.p.c. sotalol infusion attenuated the dobutamine response curve to a greater extent than i.v. (P < 0.01). In conclusion, i.p.c. infusion of sotalol and atenolol results in high cardiac tissue concentrations with low systemic drug levels. Similar antitachycardiac effects can be obtained at a 10- to 30-fold lower dose compared with i.v. delivery. Also, depression of ventricular contractility is acquired at a substantially lower i.p.c. sotalol dose. Thus, beta-blocking properties of sotalol and atenolol can be greatly enhanced by applying them i.p.c.
Collapse
Affiliation(s)
- Thomas J van Brakel
- Cardiovascular Research Institute Maastricht, Department of Cardio-thoracic Surgery, University Hospital and University Maastricht, Maastricht, The Netherlands.
| | | | | | | | | | | | | |
Collapse
|
13
|
Hermans JJR, van Essen H, Struijker-Boudier HAJ, Johnson RM, Theeuwes F, Smits JFM. Pharmacokinetic advantage of intrapericardially applied substances in the rat. J Pharmacol Exp Ther 2002; 301:672-8. [PMID: 11961072 DOI: 10.1124/jpet.301.2.672] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Intrapericardial application of therapeutic agents may open perspectives for target-directed therapy of the diseased heart. This study was performed to investigate whether intrapericardial drug application is beneficial from a pharmacokinetic point of view. Male Wistar rats were provided with intrapericardial and intravascular catheters for substance administration and sampling. Intrapericardial bolus injections of fluorescent macromolecules [fluorescein isothiocyanate (FITC)-rat IgG, molecular weight about 155 kDa; Texas Red rat serum albumin, mol. wt. 67 kDa; Texas Red fibroblast growth factor (FGF), mol. wt. 18 kDa; and FITC heparin, mean mol. wt. 18 kDa] resulted in substance concentrations in pericardial fluid that exceeded those in plasma, for several hours. Pericardial fluid volumes of catheter-instrumented rats, derived from (initial) central compartment volumes, ranged between 0.5 and 0.9 ml/kg. After chronic (7 days) intrapericardial infusions with osmotic minipumps, pericardial fluid/plasma concentration ratios (local advantages) were 7 to 10 for the fluorescent proteins and >30 for FITC-heparin. This can be explained by the low substance clearances in pericardial fluid compared with plasma. Local advantages of the small substances cortisol (mol. wt. = 362.5) and a carbonic acid derivative thereof (mol. wt. = 348) were 14 and 420. Intrapericardial infusion of (125)I-FGF-2 yielded 8 times higher cardiac tissue levels than systemic infusion, whereas (125)I-FGF-2 was found in the entire heart. Pharmacokinetic profiles of intrapericardially applied substances are such that desired local drug concentrations can be obtained at lower dosages, whereas systemic concentrations remain low (thus reducing the potential risk of peripheral side effects). Therefore, intrapericardial application of therapeutic agents provides a promising strategy for site-specific treatment of heart or coronary diseases.
Collapse
Affiliation(s)
- J J Rob Hermans
- Department of Pharmacology and Toxicology, Cardiovascular Research Institute, Universiteit Maastricht, Maastricht, The Netherlands.
| | | | | | | | | | | |
Collapse
|
14
|
Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21:2475-90. [PMID: 11055295 DOI: 10.1016/s0142-9612(00)00115-0] [Citation(s) in RCA: 1380] [Impact Index Per Article: 57.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
A considerable research has been conducted on drug delivery by biodegradable polymeric devices, following the entry of bioresorbable surgical sutures in the market about two decades ago. Amongst the different classes of biodegradable polymers, the thermoplastic aliphatic poly(esters) like poly(lactide) (PLA), poly(glycolide) (PGA), and especially the copolymer of lactide and glycolide, poly(lactide-co-glycolide) (PLGA) have generated immense interest due to their favorable properties such as good biocompatibility, biodegradability, and mechanical strength. Also, they are easy to formulate into different devices for carrying a variety of drug classes such as vaccines, peptides, proteins, and micromolecules. Also, they have been approved by the Food and Drug Administration (FDA) for drug delivery. This review discusses the various traditional and novel techniques (such as in situ microencapsulation) of preparing various drug loaded PLGA devices, with emphasis on preparing microparticles. Also, certain issues about other related biodegradable polyesters are discussed.
Collapse
Affiliation(s)
- R A Jain
- NanoSystems, a Division of Elan Pharmaceutical Technologies, King of Prussia, PA 19406, USA.
| |
Collapse
|
15
|
Elkheshen SA, Radwan MA. Sustained release microspheres of metoclopramide using poly(D,L-lactide-co-glycolide) copolymers. J Microencapsul 2000; 17:425-35. [PMID: 10898083 DOI: 10.1080/026520400405688] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
Metoclopramide was encapsulated with poly(D,L-lactide co glycolide) copolymers of different molecular weights using the emulsification/solvent evaporation technique. These polymers included poly(D,L-lactide-co-glycolide) 50:50 with inherent viscosity (i.v.) 0.2, and average molecular weight 8000, poly(D,L-lactide-co-glycolide) 50:50 with i.v. 0.8 and average molecular weight 98000 and poly(D,L-lactide-co-glycolide) 85:15 with i.v. 1.4 and average molecular weight 220000. The effect of the polymers' molecular weights as well as the polymer-to-drug ratios on the yield, the particle size distribution, and the drug content of the microspheres was investigated. The release rate of the drug was studied for 96 h in a phosphate buffer of pH 7.4. The study also investigated the effect of the new poly(lactide-co-glycolide)-H series on the characteristics of the prepared microspheres. Data revealed that a higher yield was obtained with polymers of lower molecular weights. A lower yield was also obtained with increasing the drug-to-polymer ratios for all the investigated polymers. The drug content of the microspheres was lower than expected, ranging from 49-85%, which suggested a chemical interaction between the drug and the polymers, as proved by differential scanning calorimetry (DSC) and infra red (IR) studies. A higher interaction was obtained with the H-series of the copolymers. The release of the drug mainly followed zero order kinetics on increasing either the polymers' molecular weights or the polymer-to-drug ratios. Diffusion kinetics was observed only with those batches prepared with low polymer-to-drug ratios. The release rate was a function of both the polymers' molecular weights and the drug-to-polymer ratios.
Collapse
Affiliation(s)
- S A Elkheshen
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
| | | |
Collapse
|
16
|
Jain R, Shah NH, Malick AW, Rhodes CT. Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm 1998; 24:703-27. [PMID: 9876519 DOI: 10.3109/03639049809082719] [Citation(s) in RCA: 191] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
There has been extensive research on drug delivery by biodegradable polymeric devices since bioresorbable surgical sutures entered the market two decades ago. Among the different classes of biodegradable polymers, the thermoplastic aliphatic poly(esters) such as poly(lactide) (PLA), poly(glycolide) (PGA), and especially the copolymer of lactide and glycolide referred to as poly(lactide-co-glycolide) (PLGA) have generated tremendous interest because of their excellent biocompatibility, biodegradability, and mechanical strength. They are easy to formulate into various devices for carrying a variety of drug classes such as vaccines, peptides, proteins, and micromolecules. Most importantly, they have been approved by the United States Food and Drug Administration (FDA) for drug delivery. This review presents different preparation techniques of various drug-loaded PLGA devices, with special emphasis on preparing microparticles. Certain issues about other related biodegradable polyesters are discussed.
Collapse
Affiliation(s)
- R Jain
- Department of Applied Pharmaceutical Sciences, The University of Rhode Island, Kingston 02881, USA.
| | | | | | | |
Collapse
|
17
|
Labhasetwar V, Strickberger SA, Underwood T, Davis J, Levy RJ. Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode. J Cardiovasc Pharmacol 1998; 31:449-55. [PMID: 9514191 DOI: 10.1097/00005344-199803000-00017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Atrial arrhythmias (atrial fibrillation or atrial flutter) after coronary artery bypass graft surgery are difficult to prevent or treat and often result in significant morbidity. Prior experimental studies by our group showed improved therapeutic efficacy for antiarrhythmic drugs delivered via controlled-release polymeric matrices implanted on the epicardial surface. These experiments were conducted to test the hypothesis that direct atrial epicardial administration of ibutilide from a controlled-release system (compared with intravenous administration) can reduce the inducibility of atrial flutter in the acute postoperative atrial myocardium. Polymeric sustained-release preparations were formulated by solvent casting of an ibutilide and polyurethane (Pellathane) solution in tetrahydrofurane. Multilayer solvent-casted coatings on pacing electrode wires were carried out to fabricate a sustained-release electrode system. In animal model studies, each dog underwent a thoracotomy, followed by a right atriotomy that was repaired. Induction of atrial flutter was attempted by burst pacing with the bipolar pacing catheter. Sinus rhythm was restored with overdrive pacing. After determining the induction rate (percentage) of atrial flutter in the baseline state, a stainless-steel wire coated with the drug-delivery system, 10% ibutilide/90% polyurethane (n = 7), or without drug (polyurethane coating without ibutilide, n = 5; control) was sewn onto the right atrium. Systemic intravenous administration of ibutilide (1.2 microg/kg/h) also was carried out in a separate group of animals after atriotomy (n = 5). For ibutilide (at an estimated dose of 1.2 microg/kg/h), the atrial-flutter results were 41.85 +/- 2.21% induction for baseline compared with 12.42 +/- 5.26% (p = 0.02) after the ibutilide wire implant. In the control dogs, atrial flutter was induced 29.4 +/- 4.7% at baseline and 25.2 +/- 5.1% after implantation of the control wire (p = 0.4). Ibutilide coronary venous serum concentrations at the end of the ibutilide-polyurethane electrode experiments were 2.25 +/- 0.2 ng/ml (mean +/- SEM) versus systemic levels that were below the limits of detection. Systemic intravenous ibutilide infusions had no effect on the inducibility of atrial flutter. In conclusion, an epicardial implantable electrode coating with an ibutilide controlled drug-release system significantly reduced the inducibility of atrial flutter in an experimental atriotomy model. These results suggest that atrial arrhythmias occurring after coronary bypass surgery may be prevented by local atrial administration of ibutilide from a controlled-release pacing electrode.
Collapse
Affiliation(s)
- V Labhasetwar
- University of Michigan Medical School, Ann Arbor, USA
| | | | | | | | | |
Collapse
|
18
|
Levy RJ, Labhasetwar V, Song C, Lerner E, Chen W, Vyavahare N, Qu X. Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis. J Control Release 1995. [DOI: 10.1016/0168-3659(95)00045-a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
19
|
Labhasetwar V, Underwood T, Schwendeman SP, Levy RJ. Iontophoresis for modulation of cardiac drug delivery in dogs. Proc Natl Acad Sci U S A 1995; 92:2612-6. [PMID: 7708693 PMCID: PMC42268 DOI: 10.1073/pnas.92.7.2612] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Cardiac arrhythmias are a frequent cause of death and morbidity. Conventional antiarrhythmia therapy involving oral or intravenous medication is often ineffective and complicated by drug-associated side effects. Previous studies from our laboratory have demonstrated the advantages of cardiac drug-polymer implants for enhanced efficacy for cardiac arrhythmia therapy compared with conventional administration. However, these studies were based on systems that deliver drugs at a fixed release rate. Modulation of the drug delivery rate has the advantage of regulating the amount of the drug delivered depending upon the disease state of the patient. We hypothesized that iontophoresis could be used to modulate cardiac drug delivery. In this study, we report our investigations of a cardiac drug implant in dogs that is capable of iontophoretic modulation of the administration of the antiarrhythmic agent sotalol. We used a heterogeneous cation-exchange membrane (HCM) as an electrically sensitive and highly efficient rate-limiting barrier on the cardiac-contacting surface of the implant. Thus, electric current is passed only through the HCM and not the myocardium. The iontophoretic cardiac implant demonstrated in vitro drug release rates that were responsive to current modulation. In vivo results in dogs have confirmed that iontophoresis resulted in regional coronary enhancement of sotalol levels with current-responsive increases in drug concentrations. We also observed acute current-dependent changes in ventricular effective refractory periods reflecting sotalol-induced refractoriness due to regional drug administration. In 30-day dog experiments, iontophoretic cardiac implants demonstrated robust sustained function and reproducible modulation of drug delivery kinetics.
Collapse
Affiliation(s)
- V Labhasetwar
- Division of Pediatric Cardiology, University of Michigan, Ann Arbor 48109-0576, USA
| | | | | | | |
Collapse
|